Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine versus Physician’s Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia

    Summary
    EudraCT number
    2020-003949-11
    Trial protocol
    DK   BE   DE   SE   FR   ES   IT   AT  
    Global end of trial date
    25 Mar 2024

    Results information
    Results version number
    v2(current)
    This version publication date
    20 Feb 2025
    First version publication date
    02 Jan 2025
    Other versions
    v1
    Version creation reason
    • Correction of full data set
    To update the explanation for '0000' in endpoints Event-free Survival, Duration of Complete Response and Duration of CR+CRh.

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    GS-US-546-5857
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04778397
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    jRCT2071220076: Japan Registry of Clinical Trials
    Sponsors
    Sponsor organisation name
    Gilead Sciences
    Sponsor organisation address
    333 Lakeside Drive, Foster City, CA, United States, 94404
    Public contact
    Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
    Scientific contact
    Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    25 Mar 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    25 Mar 2024
    Global end of trial reached?
    Yes
    Global end of trial date
    25 Mar 2024
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The goal of this clinical study was to compare the effectiveness of the study drugs, magrolimab in combination with azacitidine, versus venetoclax in combination with azacitidine in participants with previously untreated TP53 mutant acute myeloid leukemia (AML).
    Protection of trial subjects
    The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements. This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Jul 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 26
    Country: Number of subjects enrolled
    United States: 65
    Country: Number of subjects enrolled
    Austria: 2
    Country: Number of subjects enrolled
    Belgium: 4
    Country: Number of subjects enrolled
    France: 32
    Country: Number of subjects enrolled
    Germany: 16
    Country: Number of subjects enrolled
    Italy: 18
    Country: Number of subjects enrolled
    Spain: 35
    Country: Number of subjects enrolled
    Sweden: 1
    Country: Number of subjects enrolled
    Switzerland: 8
    Country: Number of subjects enrolled
    Hong Kong: 5
    Country: Number of subjects enrolled
    Australia: 20
    Country: Number of subjects enrolled
    Canada: 4
    Country: Number of subjects enrolled
    Japan: 21
    Worldwide total number of subjects
    257
    EEA total number of subjects
    108
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    78
    From 65 to 84 years
    172
    85 years and over
    7

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Participants were enrolled at study sites in North America, the United Kingdom, Europe, Asia, and, Australia. 1 participant was enrolled but was not randomized.

    Pre-assignment
    Screening details
    841 participants were screened.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Magrolimab + Azacitidine (Non-Intensive Therapy)
    Arm description
    Participants who were appropriate for non-intensive therapy received 1 mg/kg magrolimab intravenously (IV) on Days 1, 4; 15 mg/kg on Day 8; 30 mg/kg on Days 11, 15, and then every week (QW) x 5 weekly 30 mg/kg dose; 30 mg/kg every 2 weeks (Q2W) beginning 1 week after the 5 weekly 30 mg/kg dose. Participants received azacitidine subcutaneously (SC) or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.
    Arm type
    Experimental

    Investigational medicinal product name
    Magrolimab
    Investigational medicinal product code
    GS-4721
    Other name
    Pharmaceutical forms
    Solution for injection in vial
    Routes of administration
    Intravenous use
    Dosage and administration details
    Administered intravenously.

    Investigational medicinal product name
    Azacitidine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for injection
    Routes of administration
    Intravenous use, Subcutaneous use
    Dosage and administration details
    Administered either subcutaneously or intravenously according to region-specific drug labeling.

    Arm title
    Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy)
    Arm description
    Participants who were appropriate for non-intensive therapy received venetoclax 100 mg orally on Cycle 1 Day 1; 200 mg orally on Cycle 1 Day 2; 400 mg orally on Cycle 1 Day 3 everyday and throughout all the cycles. Participants received azacitidine SC or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.
    Arm type
    Active comparator

    Investigational medicinal product name
    Venetoclax
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Administered orally.

    Investigational medicinal product name
    Azacitidine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for injection
    Routes of administration
    Intravenous use, Subcutaneous use
    Dosage and administration details
    Administered either subcutaneously or intravenously according to region-specific drug labeling.

    Arm title
    Magrolimab + Azacitidine (Intensive Therapy)
    Arm description
    Participants who were appropriate for intensive therapy received 1 mg/kg magrolimab IV on Days 1, 4; 15 mg/kg on Day 8; 30 mg/kg on Days 11, 15, and then QW x 5 weekly 30 mg/kg dose; 30 mg/kg Q2W beginning 1 week after the 5 weekly 30 mg/kg dose. Participants received azacitidine SC or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.
    Arm type
    Experimental

    Investigational medicinal product name
    Magrolimab
    Investigational medicinal product code
    GS-4721
    Other name
    Pharmaceutical forms
    Solution for injection in vial
    Routes of administration
    Intravenous use
    Dosage and administration details
    Administered intravenously.

    Investigational medicinal product name
    Azacitidine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for injection
    Routes of administration
    Intravenous use, Subcutaneous use
    Dosage and administration details
    Administered either subcutaneously or intravenously according to region-specific drug labeling.

    Arm title
    Control Arm: 7+3 Chemotherapy (Intensive Therapy)
    Arm description
    Participants who were appropriate for intensive therapy received 7+3 chemotherapy: 7 day treatment with cytarabine 100 or 200 mg/m^2 continuous infusion and 3 day treatment with daunorubicin 60 mg/m^2 IV push or idarubicin 60 mg/m^2 IV during induction and high-dose cytarabine 1500 or 3000 mg/m^2 IV every 12 hours on Days 1, 3, and 5 up to 4 cycles and steroidal eye drops during consolidation. Each cycle was 28 days.
    Arm type
    Active comparator

    Investigational medicinal product name
    Cytarabine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Infusion
    Dosage and administration details
    Administered as continuous infusion.

    Investigational medicinal product name
    Daunorubicin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Infusion
    Dosage and administration details
    Administered intravenous peripherally.

    Investigational medicinal product name
    Idarubicin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Infusion
    Dosage and administration details
    Administered intravenously.

    Investigational medicinal product name
    Steroidal Eye Drops
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Eye drops
    Routes of administration
    Ocular use
    Dosage and administration details
    Administered per institutional standard during consolidation.

    Number of subjects in period 1
    Magrolimab + Azacitidine (Non-Intensive Therapy) Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy) Magrolimab + Azacitidine (Intensive Therapy) Control Arm: 7+3 Chemotherapy (Intensive Therapy)
    Started
    101
    104
    27
    25
    Completed
    0
    0
    0
    0
    Not completed
    101
    104
    27
    25
         Missing Study Discontinuation Reason
    1
    3
    -
    2
         Withdrew Consent
    5
    4
    1
    1
         Death
    59
    54
    11
    9
         Lost to Follow-up
    2
    1
    -
    1
         Study Terminated by Sponsor
    34
    42
    15
    12

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Magrolimab + Azacitidine (Non-Intensive Therapy)
    Reporting group description
    Participants who were appropriate for non-intensive therapy received 1 mg/kg magrolimab intravenously (IV) on Days 1, 4; 15 mg/kg on Day 8; 30 mg/kg on Days 11, 15, and then every week (QW) x 5 weekly 30 mg/kg dose; 30 mg/kg every 2 weeks (Q2W) beginning 1 week after the 5 weekly 30 mg/kg dose. Participants received azacitidine subcutaneously (SC) or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.

    Reporting group title
    Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy)
    Reporting group description
    Participants who were appropriate for non-intensive therapy received venetoclax 100 mg orally on Cycle 1 Day 1; 200 mg orally on Cycle 1 Day 2; 400 mg orally on Cycle 1 Day 3 everyday and throughout all the cycles. Participants received azacitidine SC or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.

    Reporting group title
    Magrolimab + Azacitidine (Intensive Therapy)
    Reporting group description
    Participants who were appropriate for intensive therapy received 1 mg/kg magrolimab IV on Days 1, 4; 15 mg/kg on Day 8; 30 mg/kg on Days 11, 15, and then QW x 5 weekly 30 mg/kg dose; 30 mg/kg Q2W beginning 1 week after the 5 weekly 30 mg/kg dose. Participants received azacitidine SC or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.

    Reporting group title
    Control Arm: 7+3 Chemotherapy (Intensive Therapy)
    Reporting group description
    Participants who were appropriate for intensive therapy received 7+3 chemotherapy: 7 day treatment with cytarabine 100 or 200 mg/m^2 continuous infusion and 3 day treatment with daunorubicin 60 mg/m^2 IV push or idarubicin 60 mg/m^2 IV during induction and high-dose cytarabine 1500 or 3000 mg/m^2 IV every 12 hours on Days 1, 3, and 5 up to 4 cycles and steroidal eye drops during consolidation. Each cycle was 28 days.

    Reporting group values
    Magrolimab + Azacitidine (Non-Intensive Therapy) Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy) Magrolimab + Azacitidine (Intensive Therapy) Control Arm: 7+3 Chemotherapy (Intensive Therapy) Total
    Number of subjects
    101 104 27 25 257
    Age categorical
    Units: Subjects
        Adults (18 – 64 Years)
    19 23 21 15 78
        Geriatrics (65 – 84 Years)
    79 77 6 10 172
        Geriatrics (85 Years and Over)
    3 4 0 0 7
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    70 ( 9.6 ) 71 ( 8.0 ) 57 ( 9.6 ) 61 ( 8.6 ) -
    Gender categorical
    Units: Subjects
        Female
    43 43 5 11 102
        Male
    58 61 22 14 155
    Race
    Units: Subjects
        White
    75 72 12 15 174
        Asian
    12 11 3 4 30
        Other or More Than One Race
    4 2 1 2 9
        Black or African American
    2 2 2 0 6
        Native Hawaiian or Other Pacific Islander
    0 0 1 0 1
        Not Reported
    8 17 8 4 37
    Ethnicity
    Units: Subjects
        Not Hispanic or Latino
    82 74 19 20 195
        Hispanic or Latino
    9 13 1 2 25
        Unknown or Not Reported
    10 17 7 3 37

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Magrolimab + Azacitidine (Non-Intensive Therapy)
    Reporting group description
    Participants who were appropriate for non-intensive therapy received 1 mg/kg magrolimab intravenously (IV) on Days 1, 4; 15 mg/kg on Day 8; 30 mg/kg on Days 11, 15, and then every week (QW) x 5 weekly 30 mg/kg dose; 30 mg/kg every 2 weeks (Q2W) beginning 1 week after the 5 weekly 30 mg/kg dose. Participants received azacitidine subcutaneously (SC) or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.

    Reporting group title
    Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy)
    Reporting group description
    Participants who were appropriate for non-intensive therapy received venetoclax 100 mg orally on Cycle 1 Day 1; 200 mg orally on Cycle 1 Day 2; 400 mg orally on Cycle 1 Day 3 everyday and throughout all the cycles. Participants received azacitidine SC or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.

    Reporting group title
    Magrolimab + Azacitidine (Intensive Therapy)
    Reporting group description
    Participants who were appropriate for intensive therapy received 1 mg/kg magrolimab IV on Days 1, 4; 15 mg/kg on Day 8; 30 mg/kg on Days 11, 15, and then QW x 5 weekly 30 mg/kg dose; 30 mg/kg Q2W beginning 1 week after the 5 weekly 30 mg/kg dose. Participants received azacitidine SC or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.

    Reporting group title
    Control Arm: 7+3 Chemotherapy (Intensive Therapy)
    Reporting group description
    Participants who were appropriate for intensive therapy received 7+3 chemotherapy: 7 day treatment with cytarabine 100 or 200 mg/m^2 continuous infusion and 3 day treatment with daunorubicin 60 mg/m^2 IV push or idarubicin 60 mg/m^2 IV during induction and high-dose cytarabine 1500 or 3000 mg/m^2 IV every 12 hours on Days 1, 3, and 5 up to 4 cycles and steroidal eye drops during consolidation. Each cycle was 28 days.

    Subject analysis set title
    Magrolimab + Azacitidine
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Participants who were appropriate for intensive and non-intensive therapy received 1 mg/kg magrolimab intravenously (IV) on Days 1, 4; 15 mg/kg on Day 8; 30 mg/kg on Days 11, 15, and then QW x 5 weekly 30 mg/kg dose; 30 mg/kg Q2W beginning 1 week after the 5 weekly 30 mg/kg dose. Participants received azacitidine subcutaneously (SC) or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years.

    Subject analysis set title
    Venetoclax + Azacitidine or 7+3 Chemotherapy
    Subject analysis set type
    Intention-to-treat
    Subject analysis set description
    Participants who were appropriate for non-intensive therapy received venetoclax 100 mg orally on Cycle 1 Day 1; 200 mg orally on Cycle 1 Day 2; 400 mg orally on Cycle 1 Day 3 everyday and throughout all the cycles. Participants received azacitidine SC or IV, 75 mg/m^2 on Days 1-7 or Days 1-5, 8 and 9 during every cycle of 28 days. The treatment duration was up to a maximum of 1.3 years. Participants who were appropriate for intensive therapy received 7+3 chemotherapy: 7 day treatment with cytarabine 100 or 200 mg/m^2 continuous infusion and 3 day treatment with daunorubicin 60 mg/m^2 IV push or idarubicin 60 mg/m^2 IV during induction and high-dose cytarabine 1500 or 3000 mg/m^2 IV every 12 hours on Days 1, 3, and 5 up to 4 cycles and steroidal eye drops during consolidation. Each cycle was 28 days.

    Primary: Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy

    Close Top of page
    End point title
    Overall Survival (OS) in Participants Appropriate for Non-intensive Therapy [1]
    End point description
    OS was measured from the date of randomization to the date of death from any cause. Deaths which were not observed during the study were censored at their last known alive date. Kaplan-Meier (KM) estimates were used in endpoint analysis. Participants from the Intent-to-Treat Analysis (ITT) Set who were appropriate for non-intensive therapy were analyzed. The ITT Analysis Set included all randomized participants according to the treatment arm to which the participant was randomized, unless otherwise specified. As per the pre-specified analysis, the data in this endpoint was reported only for the non-intensive therapy groups.
    End point type
    Primary
    End point timeframe
    Up to 2.1 years
    Notes
    [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As per the pre-specified analysis, the data in this endpoint was reported only for the non-intensive therapy groups.
    End point values
    Magrolimab + Azacitidine (Non-Intensive Therapy) Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy)
    Number of subjects analysed
    101
    104
    Units: months
        median (confidence interval 95%)
    4.4 (3.6 to 6.0)
    6.6 (4.8 to 8.1)
    Statistical analysis title
    OS in Participants in Non-intensive Therapy
    Statistical analysis description
    Hazard ratio and 95% CIs were calculated using the Cox proportional hazards model, adjusted for randomization stratification factors (appropriateness for non-intensive therapy vs intensive therapy, age (< 75 years, >=75 years), geographic region (US sites, outside the US sites)).
    Comparison groups
    Magrolimab + Azacitidine (Non-Intensive Therapy) v Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy)
    Number of subjects included in analysis
    205
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.507 [2]
    Method
    Stratified log-rank test
    Parameter type
    Stratified Hazard Ratio
    Point estimate
    1.132
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.783
         upper limit
    1.637
    Notes
    [2] - P-value from stratified log-rank test.

    Secondary: Overall Survival in All Participants

    Close Top of page
    End point title
    Overall Survival in All Participants
    End point description
    OS was measured from the date of randomization to the date of death from any cause. Deaths which were not observed during the study were censored at their last known alive date. KM estimates were used in endpoint analysis. Participants from the Intend-To-Treat Analysis Set were analyzed. As per the pre-specified analysis, the data for this endpoint were analyzed together for all participants for both intensive and non-intensive therapy groups.
    End point type
    Secondary
    End point timeframe
    Up to 2.1 years
    End point values
    Magrolimab + Azacitidine Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects analysed
    128
    129
    Units: months
        median (confidence interval 95%)
    4.4 (3.7 to 6.6)
    6.6 (4.9 to 8.9)
    Statistical analysis title
    OS in All Participants
    Statistical analysis description
    Hazard ratio and 95% CIs were calculated using the Cox proportional hazards model, adjusted for randomization stratification factors (appropriateness for non-intensive therapy vs intensive therapy, age (< 75 years, >=75 years), geographic region (US sites, outside the US sites)).
    Comparison groups
    Magrolimab + Azacitidine v Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects included in analysis
    257
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.3237 [3]
    Method
    Stratified Log-rank test
    Parameter type
    Stratified Hazard Ratio
    Point estimate
    1.183
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.845
         upper limit
    1.654
    Notes
    [3] - P-value from stratified log-rank test.

    Secondary: Event-Free Survival (EFS) in All Participants

    Close Top of page
    End point title
    Event-Free Survival (EFS) in All Participants
    End point description
    EFS: time from randomization to earliest relapse from CR(CR without minimal residual disease (CRMRD-) and CR with MRD positive/MRD unknown (CRMRD+/unk)), treatment failure (failure to achieve CR in 6 months of magrolimab/venetoclax+azacitidine; 2 months after chemotherapy), or death within response window. CRMRD- and CRMRD+/unk: neutrophils>1.0 ×10^9/L, platelets>100 ×10^9/L, <5% bone marrow blasts, no circulating blasts or extramedullary disease (confirmed by flow cytometry <0.1% sensitivity for CRMRD-). Post-SCT assessments or new AML therapies were included. Date of randomization was assigned as event date for participants with treatment failure. Participants without events were censored at their last assessment. KM estimates for analysis. ITT Analysis Set. Data analyzed together for magrolimab+azacitidine and venetoclax+azacitidine or chemotherapy. 9999=Upper and lower limits of CI could not be estimated due to limitation in KM model as EFS values were below quantification limit.
    End point type
    Secondary
    End point timeframe
    Up to 2.1 years
    End point values
    Magrolimab + Azacitidine Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects analysed
    128
    129
    Units: months
        median (confidence interval 95%)
    0.0 (-9999 to 9999)
    0.0 (-9999 to 9999)
    Statistical analysis title
    EFS in All Participants
    Statistical analysis description
    Hazard ratio and 95% CIs were calculated using the Cox proportional hazards model, adjusted for randomization stratification factors: therapy appropriateness, age (< 75 years, >=75 years), geographic region (US sites, outside the US sites).
    Comparison groups
    Magrolimab + Azacitidine v Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects included in analysis
    257
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.0661 [4]
    Method
    Stratified Log-rank test
    Parameter type
    Stratified Hazard Ratio
    Point estimate
    1.389
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    1.043
         upper limit
    1.848
    Notes
    [4] - P-value for comparing the event free survival functions from the two treatment groups was from stratified log-rank test, adjusted for randomization.

    Secondary: Rate of Complete Remission (CR) in All Participants

    Close Top of page
    End point title
    Rate of Complete Remission (CR) in All Participants
    End point description
    Rate of CR was the percentage of participants who achieved a CR, including CR without minimal residual disease (CR MRD-) and CR with positive or unknown minimal residual disease (CR MRD+/unk) within 6 months of treatment with magrolimab + azacitidine or venetoclax + azacitidine, or within 2 months of treatment with chemotherapy, as defined by investigators based on European Leukemia Net (ELN) 2017 AML (ELN 2017 AML) with modifications, while on study prior to initiation of any new anti-AML therapy or stem cell transplant (SCT) within the response assessment window of 2.1 years. CR MRD- and CR MRD+/unk were defined in endpoint #3 (EFS). Percentages were rounded-off. Clopper-Pearson method were used in endpoint analysis. Participants from ITT Analysis Set were analyzed. As per the pre-specified analysis, the data for this endpoint were analyzed together for all participants who received magrolimab + azacitidine and participants who received venetoclax + azacitidine or chemotherapy.
    End point type
    Secondary
    End point timeframe
    Up to 2.1 years
    End point values
    Magrolimab + Azacitidine Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects analysed
    128
    129
    Units: percentage of participants
        number (confidence interval 95%)
    9.4 (4.9 to 15.8)
    29.5 (21.8 to 38.1)
    Statistical analysis title
    Rate of CR in All Participants
    Statistical analysis description
    Odds ratio and 2-sided 95% CI were calculated from stratum-adjusted Mantel-Haenszel estimates adjusted for randomization stratification factors (appropriateness for non-intensive therapy versus intensive therapy, age (< 75 years, >=75 years), geographic region (US sites, outside US sites)).
    Comparison groups
    Magrolimab + Azacitidine v Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects included in analysis
    257
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Stratified Odds Ratio
    Point estimate
    0.25
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.123
         upper limit
    0.506

    Secondary: Rate of CR Without Minimal Residual Disease (CR MRD-) in All Participants

    Close Top of page
    End point title
    Rate of CR Without Minimal Residual Disease (CR MRD-) in All Participants
    End point description
    Rate of CR MRD- was the percentage of participants who achieve a CR MRD- within 6 months treatment with magrolimab + azacitidine or venetoclax + azacitidine, or within 2 months of treatment with 7 + 3 chemotherapy, as defined by investigators based on ELN 2017 AML with modifications, while on study prior to initiation of any new anti-AML therapy or SCT within the response assessment window of 2.1 years. CR MRD- is defined in endpoint #3 (EFS). Percentages were rounded-off. Clopper-Pearson method were used in endpoint analysis. Participants from the Intent-To-Treat Analysis Set were analyzed. As per the pre-specified analysis, the data for this endpoint were analyzed together for all participants who received magrolimab + azacitidine and participants who received venetoclax + azacitidine or 7+3 chemotherapy.
    End point type
    Secondary
    End point timeframe
    Up to 2.1 years
    End point values
    Magrolimab + Azacitidine Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects analysed
    128
    129
    Units: percentage of participants
        number (confidence interval 95%)
    0.8 (0.0 to 4.3)
    10.1 (5.5 to 16.6)
    Statistical analysis title
    Rate of CR MRD- in All Participants
    Statistical analysis description
    Odds ratio and 2-sided 95% CI were calculated from stratum-adjusted Mantel-Haenszel estimates adjusted for randomization stratification factors (appropriateness for non-intensive therapy versus intensive therapy, age (< 75 years, >=75 years), geographic region (US sites, outside US sites)).
    Comparison groups
    Magrolimab + Azacitidine v Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects included in analysis
    257
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Stratified Odds Ratio
    Point estimate
    0.072
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.009
         upper limit
    0.559

    Secondary: Rate of CR and CR with Partial Hematologic Recovery (CR+CRh) in All Participants

    Close Top of page
    End point title
    Rate of CR and CR with Partial Hematologic Recovery (CR+CRh) in All Participants
    End point description
    CR+CRh rate was the percentage of participants who achieved a CR (including CR MRD- and CR MRD+/unk) or CRh as defined by CR with partial platelet and absolute neutrophil count (ANC) recovery while on study prior to initiation of any new anti-AML therapy or SCT up to the response assessment window of 2.1 years. CRh is defined as neutrophils > 0.5 x 10^9/L; platelets > 50 x 10^9/L; bone marrow blasts < 5%; Absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease. CR MRD- and CR MRD+/unk are defined in endpoint #3 (EFS). Percentages were rounded-off. Clopper-Pearson method were used in endpoint analysis. Participants from the Intent-To-Treat Analysis Set were analyzed. As per the pre-specified analysis, the data for this endpoint were analyzed together for all participants who received magrolimab + azacitidine and participants who received venetoclax + azacitidine or 7+3 chemotherapy.
    End point type
    Secondary
    End point timeframe
    Up to 2.1 years
    End point values
    Magrolimab + Azacitidine Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects analysed
    128
    129
    Units: percentage of participants
        number (confidence interval 95%)
    10.2 (5.5 to 16.7)
    34.1 (26.0 to 43.0)
    Statistical analysis title
    Rate of CR+CRh in All Participants
    Statistical analysis description
    Odds ratio and 2-sided 95% CI were calculated from stratum-adjusted Mantel-Haenszel estimates adjusted for randomization stratification factors (appropriateness for non-intensive therapy versus intensive therapy, age (< 75 years, >=75 years), geographic region (US sites, outside US sites)).
    Comparison groups
    Magrolimab + Azacitidine v Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects included in analysis
    257
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    Method
    Parameter type
    Stratified Odds Ratio
    Point estimate
    0.215
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.108
         upper limit
    0.428

    Secondary: Duration of Complete Remission (DCR)

    Close Top of page
    End point title
    Duration of Complete Remission (DCR)
    End point description
    DCR was measured from first assessment meeting CR criteria (including CR MRD- and CR MRD+/unk) within 6 months of magrolimab/venetoclax + azacitidine; 2 months of chemotherapy, until AML relapse or death (including post-SCT). Participants without relapse or death or starting new anti-AML therapies (excluding post-SCT maintenance therapy) before relapse were censored at last response assessment or last assessment prior to starting new treatment respectively. CR MRD- and CR MRD+/unk defined in Endpoint #3 (EFS). KM estimates were used for analysis. Participants from ITT Analysis Set who achieved CR within 6 months in all participants (2 months for participants receiving 7 + 3 chemotherapy) were analyzed. Data analyzed together for magrolimab+azacitidine and venetoclax+azacitidine or chemotherapy. '9999'=Upper limit of CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to 2.1 years
    End point values
    Magrolimab + Azacitidine Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects analysed
    12
    38
    Units: months
        median (confidence interval 95%)
    9.5 (2.0 to 9999)
    4.9 (3.1 to 6.5)
    No statistical analyses for this end point

    Secondary: Duration of CR+CRh

    Close Top of page
    End point title
    Duration of CR+CRh
    End point description
    Duration of CR+CRh was measured from first assessment meeting CR criteria (CR MRD- and CR MRD+/unk) or CRh in 6 months of magrolimab/venetoclax+azacitidine; 2 months of chemotherapy, until AML relapse or death (including post-SCT). Participants without relapse or death or starting new anti-AML therapies (excluding post-SCT maintenance therapy) before relapse were censored at their last response assessment or last assessment prior to starting new treatment. CR MRD-, CR MRD+/unk defined in endpoint#3, CRh defined in endpoint#6. KM estimates were used for analysis. Participants from ITT Analysis Set who achieved CR within 6 months in all participants (2 months for participants receiving chemotherapy were analyzed. Data analyzed together for magrolimab+azacitidine and venetoclax+azacitidine or chemotherapy. '9999'=Upper limit of CI was not estimable due to insufficient number of participants with events.
    End point type
    Secondary
    End point timeframe
    Up to 2.1 years
    End point values
    Magrolimab + Azacitidine Venetoclax + Azacitidine or 7+3 Chemotherapy
    Number of subjects analysed
    13
    44
    Units: months
        median (confidence interval 95%)
    9.5 (2.0 to 9999)
    4.9 (3.1 to 6.5)
    No statistical analyses for this end point

    Secondary: Percentage of Participants Experiencing Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0

    Close Top of page
    End point title
    Percentage of Participants Experiencing Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0
    End point description
    TEAEs were defined as any AE that began on or after the date of first dose of study treatment up to the date of last dose of study treatment plus 70 days or the day before initiation of new anti-AML therapy including SCT, whichever occurred first. The Safety Analysis Set included all participants who took at least 1 dose of any study treatment, with treatment assignment designated according to the actual treatment received.
    End point type
    Secondary
    End point timeframe
    First dose date up to 1.3 years plus 70 days
    End point values
    Magrolimab + Azacitidine (Non-Intensive Therapy) Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy) Magrolimab + Azacitidine (Intensive Therapy) Control Arm: 7+3 Chemotherapy (Intensive Therapy)
    Number of subjects analysed
    96
    98
    27
    23
    Units: percentage of participants
        number (not applicable)
    96.9
    95.9
    92.6
    95.7
    No statistical analyses for this end point

    Secondary: Percentage of Participants Experiencing Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0

    Close Top of page
    End point title
    Percentage of Participants Experiencing Grade 3 or 4 Treatment-Emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0
    End point description
    Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study treatment plus 70 days or the day before initiation of any new anti-AML therapy including SCT, whichever occurred first. Percentages were rounded-off. Participants from Safety Analysis Set were analyzed.
    End point type
    Secondary
    End point timeframe
    First dose date up to 1.3 years plus 70 days
    End point values
    Magrolimab + Azacitidine (Non-Intensive Therapy) Control Arm: Venetoclax + Azacitidine (Non-Intensive Therapy) Magrolimab + Azacitidine (Intensive Therapy) Control Arm: 7+3 Chemotherapy (Intensive Therapy)
    Number of subjects analysed
    96
    98
    27
    23
    Units: percentage of participants
    number (not applicable)
        Grade 3 or 4
    96.9
    99.0
    100
    95.7
    No statistical analyses for this end point

    Secondary: Serum Concentration of Magrolimab

    Close Top of page
    End point title
    Serum Concentration of Magrolimab
    End point description
    The Pharmacokinetic (PK) Analysis Set included all randomized participants who took at least one dose of magrolimab and have at least 1 measurable (non-below the limit of quantitation (BLQ) numeric values) posttreatment serum concentration of magrolimab. Participants with available data were analyzed. '9999'= Standard deviation cannot be calculated for 1 participant.
    End point type
    Secondary
    End point timeframe
    Predose on Days 1, 4, 8, 11; Days 29 and 57 Predose and 1 hour Postdose; Predose on Days 113, 169, 253, 281 and 337
    End point values
    Magrolimab + Azacitidine
    Number of subjects analysed
    88 [5]
    Units: μg/mL
    arithmetic mean (standard deviation)
        Day 1 Predose
    0.0 ( 0.0 )
        Day 4 Predose
    0.0 ( 9999 )
        Day 8 Predose
    0.0 ( 0.0 )
        Day 11 Predose
    111 ( 9999 )
        Day 29 Predose
    311 ( 195 )
        Day 29 1 hour Postdose
    376 ( 9999 )
        Day 57 Predose
    402 ( 262 )
        Day 57 1 hour Postdose
    967 ( 351 )
        Day 113 Predose
    138 ( 96.0 )
        Day 169 Predose
    198 ( 129 )
        Day 253 Predose
    294 ( 181 )
        Day 281 Predose
    263 ( 9999 )
        Day 337 Predose
    251 ( 114 )
    Notes
    [5] - n= 88, 1, 83, 1, 69, 1, 43, 36, 20, 10, 8, 1, 3
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Anti-Magrolimab Antibodies

    Close Top of page
    End point title
    Percentage of Participants with Anti-Magrolimab Antibodies [6]
    End point description
    Percentages were rounded-off. The Immunogenicity Analysis Set included all randomized participants who received at least one dose of magrolimab and had at least one evaluable anti-magrolimab antibody test result.
    End point type
    Secondary
    End point timeframe
    Up to 2.1 years
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: As per the pre-specified analysis, the data in this endpoint was reported only for the non-intensive therapy groups.
    End point values
    Magrolimab + Azacitidine (Non-Intensive Therapy) Magrolimab + Azacitidine (Intensive Therapy)
    Number of subjects analysed
    93
    27
    Units: percentage of participants
        number (not applicable)
    10.4
    11.1
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    All-cause mortality: Up to 2.1 years; Adverse events: Up to 1.3 years plus 70 days
    Adverse event reporting additional description
    Death: ITT Analysis Set included all participants who were randomized in study, with treatment assignment designated according to treatment arm participant was randomized to. AEs: Safety Analysis Set included all participants who took at least 1 dose of any study drugs, with treatment assignment designated according to actual treatment received.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.1
    Reporting groups
    Reporting group title
    Appropriate for Non-intensive Therapy Magro + Aza
    Reporting group description
    Patients who received Appropriate for Non-intensive Therapy Magro + Aza

    Reporting group title
    Appropriate for Non-intensive Therapy Ven + Aza
    Reporting group description
    Patients who received Appropriate for Non-intensive Therapy Ven + Aza

    Reporting group title
    Appropriate for intensive Therapy Magro + Aza
    Reporting group description
    Patients who received Appropriate for intensive Therapy Magro + Aza

    Reporting group title
    Appropriate for intensive Therapy 7+3 Chemo
    Reporting group description
    Patients who received Appropriate for intensive Therapy 7+3 Chemo

    Serious adverse events
    Appropriate for Non-intensive Therapy Magro + Aza Appropriate for Non-intensive Therapy Ven + Aza Appropriate for intensive Therapy Magro + Aza Appropriate for intensive Therapy 7+3 Chemo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    84 / 96 (87.50%)
    76 / 98 (77.55%)
    20 / 27 (74.07%)
    14 / 23 (60.87%)
         number of deaths (all causes)
    61
    57
    14
    10
         number of deaths resulting from adverse events
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Ovarian cancer recurrent
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Embolism
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Shock
         subjects affected / exposed
    1 / 96 (1.04%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    2 / 96 (2.08%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haematoma
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Multiple organ dysfunction syndrome
         subjects affected / exposed
    2 / 96 (2.08%)
    1 / 98 (1.02%)
    1 / 27 (3.70%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    1 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 2
    0 / 1
    1 / 1
    0 / 1
    Asthenia
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    10 / 96 (10.42%)
    4 / 98 (4.08%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    4 / 10
    1 / 4
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fatigue
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Device related thrombosis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sudden death
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Immune system disorders
    Anaphylactic reaction
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemophagocytic lymphohistiocytosis
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    Reproductive system and breast disorders
    Prostatitis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    3 / 96 (3.13%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed
    2 / 96 (2.08%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute respiratory failure
         subjects affected / exposed
    2 / 96 (2.08%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung disorder
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    0 / 96 (0.00%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory distress
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypercapnia
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary alveolar haemorrhage
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Organising pneumonia
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lung infiltration
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary oedema
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Platelet count decreased
         subjects affected / exposed
    3 / 96 (3.13%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood bilirubin increased
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutrophil count decreased
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymphocyte count decreased
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Liver function test increased
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood glucose increased
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood creatinine increased
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Subdural haematoma
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal fracture
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fractured sacrum
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fall
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Transfusion reaction
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infusion related reaction
         subjects affected / exposed
    5 / 96 (5.21%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    5 / 5
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Cardiac failure
         subjects affected / exposed
    3 / 96 (3.13%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    Cardiac arrest
         subjects affected / exposed
    1 / 96 (1.04%)
    2 / 98 (2.04%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac tamponade
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute myocardial infarction
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Angina pectoris
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myocardial ischaemia
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Left ventricular failure
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiogenic shock
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac failure acute
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pericardial effusion
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ventricular tachycardia
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Seizure
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhage intracranial
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Encephalopathy
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Syncope
         subjects affected / exposed
    1 / 96 (1.04%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dizziness postural
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral small vessel ischaemic ~ disease
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebral infarction
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Cerebral haemorrhage
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lethargy
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorder
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Spinal cord compression
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    32 / 96 (33.33%)
    34 / 98 (34.69%)
    7 / 27 (25.93%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    13 / 47
    25 / 46
    4 / 9
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    Anaemia
         subjects affected / exposed
    9 / 96 (9.38%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    6 / 9
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cytopenia
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile bone marrow aplasia
         subjects affected / exposed
    1 / 96 (1.04%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Disseminated intravascular ~ coagulation
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemolysis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemolytic anaemia
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancytopenia
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Red blood cell abnormality
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Retinal vascular thrombosis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Retinal haemorrhage
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Orbital haematoma
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    0 / 96 (0.00%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    2 / 96 (2.08%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 2
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal strangulated hernia
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Anal fistula
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis ischaemic
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea haemorrhagic
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhoids
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Haemorrhoids thrombosed
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestine perforation
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenic colitis
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Toothache
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pancreatitis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholecystitis acute
         subjects affected / exposed
    0 / 96 (0.00%)
    2 / 98 (2.04%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Acute kidney injury
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Chronic kidney disease
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Oliguria
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract obstruction
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary retention
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal failure
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Muscular weakness
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bone pain
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal chest pain
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    13 / 96 (13.54%)
    10 / 98 (10.20%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 13
    4 / 10
    2 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    2 / 5
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    7 / 96 (7.29%)
    5 / 98 (5.10%)
    3 / 27 (11.11%)
    3 / 23 (13.04%)
         occurrences causally related to treatment / all
    1 / 7
    0 / 6
    0 / 3
    0 / 3
         deaths causally related to treatment / all
    0 / 3
    0 / 1
    0 / 0
    0 / 0
    Neutropenic sepsis
         subjects affected / exposed
    3 / 96 (3.13%)
    3 / 98 (3.06%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    2 / 3
    2 / 3
    2 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    3 / 96 (3.13%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    2 / 4
    1 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    2 / 96 (2.08%)
    4 / 98 (4.08%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 2
    2 / 4
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    Anorectal infection
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    1 / 27 (3.70%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacteraemia
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Atypical pneumonia
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia fungal
         subjects affected / exposed
    1 / 96 (1.04%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    2 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 3
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pseudomonal sepsis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia sepsis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Anal fistula infection
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Clostridial sepsis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Bronchopulmonary aspergillosis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacterial infection
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Appendicitis perforated
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Covid-19
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Dermo-hypodermitis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Device related sepsis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diverticulitis intestinal perforated
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Endophthalmitis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Enterococcal bacteraemia
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Erysipelas
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Escherichia bacteraemia
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Klebsiella infection
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Klebsiella sepsis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lymph node tuberculosis
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mediastinitis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    Parainfluenzae virus infection
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Parotitis
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumocystis jirovecii infection
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Periorbital infection
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Perineal abscess
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia pseudomonal
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Respiratory tract infection fungal
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal infection
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Soft tissue infection
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Rhinocerebral mucormycosis
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Respiratory tract infection viral
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal sepsis
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Wound infection
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular device infection
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tooth infection
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Streptococcal bacteraemia
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    0 / 96 (0.00%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diabetic ketoacidosis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Failure to thrive
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperglycaemic hyperosmolar ~ nonketotic syndrome
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypervolaemia
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Tumour lysis syndrome
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolic acidosis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Appropriate for Non-intensive Therapy Magro + Aza Appropriate for Non-intensive Therapy Ven + Aza Appropriate for intensive Therapy Magro + Aza Appropriate for intensive Therapy 7+3 Chemo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    92 / 96 (95.83%)
    94 / 98 (95.92%)
    27 / 27 (100.00%)
    23 / 23 (100.00%)
    Vascular disorders
    Hypotension
         subjects affected / exposed
    12 / 96 (12.50%)
    6 / 98 (6.12%)
    2 / 27 (7.41%)
    1 / 23 (4.35%)
         occurrences all number
    13
    7
    2
    1
    Haematoma
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    1
    1
    0
    2
    Hypertension
         subjects affected / exposed
    1 / 96 (1.04%)
    5 / 98 (5.10%)
    2 / 27 (7.41%)
    5 / 23 (21.74%)
         occurrences all number
    1
    7
    2
    5
    General disorders and administration site conditions
    Oedema peripheral
         subjects affected / exposed
    17 / 96 (17.71%)
    19 / 98 (19.39%)
    4 / 27 (14.81%)
    6 / 23 (26.09%)
         occurrences all number
    21
    24
    4
    7
    Fatigue
         subjects affected / exposed
    24 / 96 (25.00%)
    20 / 98 (20.41%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    32
    21
    3
    0
    Pyrexia
         subjects affected / exposed
    40 / 96 (41.67%)
    24 / 98 (24.49%)
    11 / 27 (40.74%)
    7 / 23 (30.43%)
         occurrences all number
    64
    37
    17
    10
    Generalised oedema
         subjects affected / exposed
    2 / 96 (2.08%)
    1 / 98 (1.02%)
    2 / 27 (7.41%)
    2 / 23 (8.70%)
         occurrences all number
    2
    1
    2
    2
    Non-cardiac chest pain
         subjects affected / exposed
    3 / 96 (3.13%)
    5 / 98 (5.10%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    3
    7
    0
    0
    Asthenia
         subjects affected / exposed
    13 / 96 (13.54%)
    13 / 98 (13.27%)
    3 / 27 (11.11%)
    1 / 23 (4.35%)
         occurrences all number
    13
    14
    3
    1
    Oedema
         subjects affected / exposed
    3 / 96 (3.13%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    6 / 23 (26.09%)
         occurrences all number
    3
    0
    1
    6
    Chills
         subjects affected / exposed
    9 / 96 (9.38%)
    4 / 98 (4.08%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    11
    4
    0
    0
    Injection site reaction
         subjects affected / exposed
    5 / 96 (5.21%)
    15 / 98 (15.31%)
    3 / 27 (11.11%)
    0 / 23 (0.00%)
         occurrences all number
    13
    21
    3
    0
    Mucosal inflammation
         subjects affected / exposed
    3 / 96 (3.13%)
    2 / 98 (2.04%)
    2 / 27 (7.41%)
    1 / 23 (4.35%)
         occurrences all number
    3
    2
    2
    1
    Respiratory, thoracic and mediastinal disorders
    Hypoxia
         subjects affected / exposed
    9 / 96 (9.38%)
    6 / 98 (6.12%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    10
    7
    0
    0
    Pleural effusion
         subjects affected / exposed
    11 / 96 (11.46%)
    5 / 98 (5.10%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    11
    6
    0
    2
    Cough
         subjects affected / exposed
    9 / 96 (9.38%)
    10 / 98 (10.20%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    9
    11
    0
    0
    Epistaxis
         subjects affected / exposed
    8 / 96 (8.33%)
    15 / 98 (15.31%)
    3 / 27 (11.11%)
    1 / 23 (4.35%)
         occurrences all number
    9
    16
    3
    1
    Dyspnoea
         subjects affected / exposed
    18 / 96 (18.75%)
    16 / 98 (16.33%)
    2 / 27 (7.41%)
    2 / 23 (8.70%)
         occurrences all number
    25
    17
    2
    2
    Respiratory failure
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    2
    Oropharyngeal pain
         subjects affected / exposed
    7 / 96 (7.29%)
    6 / 98 (6.12%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    9
    6
    2
    0
    Pulmonary oedema
         subjects affected / exposed
    5 / 96 (5.21%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    5
    2
    0
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    9 / 96 (9.38%)
    6 / 98 (6.12%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    9
    6
    2
    0
    Anxiety
         subjects affected / exposed
    5 / 96 (5.21%)
    5 / 98 (5.10%)
    1 / 27 (3.70%)
    3 / 23 (13.04%)
         occurrences all number
    5
    5
    1
    3
    Confusional state
         subjects affected / exposed
    5 / 96 (5.21%)
    5 / 98 (5.10%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    5
    5
    0
    0
    Investigations
    Platelet count decreased
         subjects affected / exposed
    17 / 96 (17.71%)
    24 / 98 (24.49%)
    4 / 27 (14.81%)
    2 / 23 (8.70%)
         occurrences all number
    34
    52
    4
    2
    Blood bilirubin increased
         subjects affected / exposed
    19 / 96 (19.79%)
    11 / 98 (11.22%)
    3 / 27 (11.11%)
    2 / 23 (8.70%)
         occurrences all number
    23
    12
    3
    2
    Neutrophil count decreased
         subjects affected / exposed
    9 / 96 (9.38%)
    22 / 98 (22.45%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    28
    42
    3
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    13 / 96 (13.54%)
    9 / 98 (9.18%)
    2 / 27 (7.41%)
    2 / 23 (8.70%)
         occurrences all number
    13
    15
    2
    2
    Blood creatinine increased
         subjects affected / exposed
    8 / 96 (8.33%)
    14 / 98 (14.29%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences all number
    9
    26
    1
    0
    Alanine aminotransferase increased
         subjects affected / exposed
    13 / 96 (13.54%)
    6 / 98 (6.12%)
    2 / 27 (7.41%)
    1 / 23 (4.35%)
         occurrences all number
    15
    9
    2
    1
    White blood cell count decreased
         subjects affected / exposed
    6 / 96 (6.25%)
    14 / 98 (14.29%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences all number
    16
    26
    1
    0
    Weight decreased
         subjects affected / exposed
    9 / 96 (9.38%)
    8 / 98 (8.16%)
    1 / 27 (3.70%)
    1 / 23 (4.35%)
         occurrences all number
    9
    8
    1
    1
    Blood alkaline phosphatase increased
         subjects affected / exposed
    6 / 96 (6.25%)
    10 / 98 (10.20%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    7
    12
    0
    0
    Lymphocyte count decreased
         subjects affected / exposed
    4 / 96 (4.17%)
    11 / 98 (11.22%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    4
    34
    0
    0
    Injury, poisoning and procedural complications
    Infusion related reaction
         subjects affected / exposed
    19 / 96 (19.79%)
    3 / 98 (3.06%)
    5 / 27 (18.52%)
    1 / 23 (4.35%)
         occurrences all number
    25
    4
    6
    2
    Fall
         subjects affected / exposed
    9 / 96 (9.38%)
    10 / 98 (10.20%)
    3 / 27 (11.11%)
    2 / 23 (8.70%)
         occurrences all number
    10
    10
    6
    2
    Contusion
         subjects affected / exposed
    6 / 96 (6.25%)
    5 / 98 (5.10%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences all number
    7
    5
    1
    0
    Allergic transfusion reaction
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    3 / 23 (13.04%)
         occurrences all number
    0
    1
    0
    3
    Cardiac disorders
    Tachycardia
         subjects affected / exposed
    5 / 96 (5.21%)
    4 / 98 (4.08%)
    2 / 27 (7.41%)
    2 / 23 (8.70%)
         occurrences all number
    5
    5
    2
    2
    Sinus tachycardia
         subjects affected / exposed
    6 / 96 (6.25%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    8
    2
    0
    0
    Atrial fibrillation
         subjects affected / exposed
    5 / 96 (5.21%)
    6 / 98 (6.12%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    9
    6
    0
    1
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    7 / 96 (7.29%)
    8 / 98 (8.16%)
    2 / 27 (7.41%)
    1 / 23 (4.35%)
         occurrences all number
    12
    9
    3
    1
    Dysgeusia
         subjects affected / exposed
    5 / 96 (5.21%)
    6 / 98 (6.12%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    5
    7
    0
    0
    Presyncope
         subjects affected / exposed
    3 / 96 (3.13%)
    0 / 98 (0.00%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    3
    0
    2
    0
    Headache
         subjects affected / exposed
    13 / 96 (13.54%)
    11 / 98 (11.22%)
    5 / 27 (18.52%)
    2 / 23 (8.70%)
         occurrences all number
    13
    14
    5
    2
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    25 / 96 (26.04%)
    28 / 98 (28.57%)
    7 / 27 (25.93%)
    5 / 23 (21.74%)
         occurrences all number
    49
    45
    7
    5
    Thrombocytopenia
         subjects affected / exposed
    8 / 96 (8.33%)
    16 / 98 (16.33%)
    3 / 27 (11.11%)
    5 / 23 (21.74%)
         occurrences all number
    8
    20
    3
    6
    Haemolysis
         subjects affected / exposed
    7 / 96 (7.29%)
    0 / 98 (0.00%)
    4 / 27 (14.81%)
    0 / 23 (0.00%)
         occurrences all number
    7
    0
    4
    0
    Neutropenia
         subjects affected / exposed
    8 / 96 (8.33%)
    26 / 98 (26.53%)
    1 / 27 (3.70%)
    3 / 23 (13.04%)
         occurrences all number
    12
    46
    2
    4
    Febrile neutropenia
         subjects affected / exposed
    20 / 96 (20.83%)
    25 / 98 (25.51%)
    7 / 27 (25.93%)
    11 / 23 (47.83%)
         occurrences all number
    23
    32
    10
    13
    Gastrointestinal disorders
    Constipation
         subjects affected / exposed
    33 / 96 (34.38%)
    37 / 98 (37.76%)
    13 / 27 (48.15%)
    4 / 23 (17.39%)
         occurrences all number
    47
    45
    20
    4
    Diarrhoea
         subjects affected / exposed
    27 / 96 (28.13%)
    38 / 98 (38.78%)
    5 / 27 (18.52%)
    9 / 23 (39.13%)
         occurrences all number
    39
    51
    5
    9
    Nausea
         subjects affected / exposed
    27 / 96 (28.13%)
    32 / 98 (32.65%)
    11 / 27 (40.74%)
    6 / 23 (26.09%)
         occurrences all number
    39
    49
    14
    6
    Vomiting
         subjects affected / exposed
    15 / 96 (15.63%)
    22 / 98 (22.45%)
    4 / 27 (14.81%)
    1 / 23 (4.35%)
         occurrences all number
    18
    25
    6
    1
    Stomatitis
         subjects affected / exposed
    5 / 96 (5.21%)
    15 / 98 (15.31%)
    3 / 27 (11.11%)
    6 / 23 (26.09%)
         occurrences all number
    5
    16
    3
    6
    Abdominal pain
         subjects affected / exposed
    11 / 96 (11.46%)
    11 / 98 (11.22%)
    3 / 27 (11.11%)
    2 / 23 (8.70%)
         occurrences all number
    13
    11
    3
    2
    Haemorrhoids
         subjects affected / exposed
    5 / 96 (5.21%)
    8 / 98 (8.16%)
    3 / 27 (11.11%)
    1 / 23 (4.35%)
         occurrences all number
    5
    8
    3
    1
    Abdominal pain upper
         subjects affected / exposed
    6 / 96 (6.25%)
    6 / 98 (6.12%)
    1 / 27 (3.70%)
    1 / 23 (4.35%)
         occurrences all number
    6
    7
    1
    1
    Dyspepsia
         subjects affected / exposed
    4 / 96 (4.17%)
    6 / 98 (6.12%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    6
    6
    2
    0
    Enterocolitis
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    2
    Colitis
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    1 / 27 (3.70%)
    3 / 23 (13.04%)
         occurrences all number
    1
    0
    1
    3
    Gastrooesophageal reflux disease
         subjects affected / exposed
    2 / 96 (2.08%)
    0 / 98 (0.00%)
    2 / 27 (7.41%)
    2 / 23 (8.70%)
         occurrences all number
    2
    0
    2
    2
    Dry mouth
         subjects affected / exposed
    2 / 96 (2.08%)
    3 / 98 (3.06%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    3
    3
    2
    0
    Proctalgia
         subjects affected / exposed
    0 / 96 (0.00%)
    8 / 98 (8.16%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    0
    8
    2
    0
    Tongue coated
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    0
    0
    2
    0
    Hepatobiliary disorders
    Hyperbilirubinaemia
         subjects affected / exposed
    4 / 96 (4.17%)
    6 / 98 (6.12%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    5
    6
    2
    0
    Skin and subcutaneous tissue disorders
    Petechiae
         subjects affected / exposed
    4 / 96 (4.17%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    5
    3
    0
    2
    Night sweats
         subjects affected / exposed
    0 / 96 (0.00%)
    3 / 98 (3.06%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    0
    4
    2
    0
    Toxic skin eruption
         subjects affected / exposed
    0 / 96 (0.00%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    3 / 23 (13.04%)
         occurrences all number
    0
    1
    0
    4
    Rash
         subjects affected / exposed
    3 / 96 (3.13%)
    9 / 98 (9.18%)
    0 / 27 (0.00%)
    4 / 23 (17.39%)
         occurrences all number
    3
    10
    0
    5
    Erythema
         subjects affected / exposed
    4 / 96 (4.17%)
    5 / 98 (5.10%)
    3 / 27 (11.11%)
    1 / 23 (4.35%)
         occurrences all number
    4
    7
    3
    1
    Rash maculo-papular
         subjects affected / exposed
    6 / 96 (6.25%)
    5 / 98 (5.10%)
    1 / 27 (3.70%)
    2 / 23 (8.70%)
         occurrences all number
    6
    5
    1
    2
    Rash macular
         subjects affected / exposed
    1 / 96 (1.04%)
    0 / 98 (0.00%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    1
    0
    2
    0
    Purpura
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    2
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    5 / 96 (5.21%)
    6 / 98 (6.12%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    5
    6
    0
    1
    Acute kidney injury
         subjects affected / exposed
    5 / 96 (5.21%)
    4 / 98 (4.08%)
    2 / 27 (7.41%)
    1 / 23 (4.35%)
         occurrences all number
    6
    4
    2
    1
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    11 / 96 (11.46%)
    10 / 98 (10.20%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences all number
    11
    10
    1
    0
    Back pain
         subjects affected / exposed
    9 / 96 (9.38%)
    6 / 98 (6.12%)
    1 / 27 (3.70%)
    1 / 23 (4.35%)
         occurrences all number
    9
    6
    1
    1
    Pain in extremity
         subjects affected / exposed
    5 / 96 (5.21%)
    8 / 98 (8.16%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences all number
    5
    9
    1
    0
    Bone pain
         subjects affected / exposed
    2 / 96 (2.08%)
    1 / 98 (1.02%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    2
    1
    0
    2
    Infections and infestations
    Pneumonia
         subjects affected / exposed
    10 / 96 (10.42%)
    10 / 98 (10.20%)
    2 / 27 (7.41%)
    3 / 23 (13.04%)
         occurrences all number
    10
    10
    2
    3
    Influenza
         subjects affected / exposed
    0 / 96 (0.00%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    0
    0
    0
    2
    Oral herpes
         subjects affected / exposed
    1 / 96 (1.04%)
    1 / 98 (1.02%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    1
    1
    2
    0
    Furuncle
         subjects affected / exposed
    0 / 96 (0.00%)
    2 / 98 (2.04%)
    2 / 27 (7.41%)
    0 / 23 (0.00%)
         occurrences all number
    0
    3
    2
    0
    Urinary tract infection
         subjects affected / exposed
    5 / 96 (5.21%)
    0 / 98 (0.00%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    5
    0
    0
    0
    Staphylococcal bacteraemia
         subjects affected / exposed
    1 / 96 (1.04%)
    2 / 98 (2.04%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    1
    3
    0
    2
    Sepsis
         subjects affected / exposed
    2 / 96 (2.08%)
    3 / 98 (3.06%)
    1 / 27 (3.70%)
    2 / 23 (8.70%)
         occurrences all number
    2
    3
    2
    4
    Metabolism and nutrition disorders
    Hypokalaemia
         subjects affected / exposed
    21 / 96 (21.88%)
    22 / 98 (22.45%)
    5 / 27 (18.52%)
    8 / 23 (34.78%)
         occurrences all number
    37
    39
    5
    9
    Decreased appetite
         subjects affected / exposed
    20 / 96 (20.83%)
    21 / 98 (21.43%)
    2 / 27 (7.41%)
    3 / 23 (13.04%)
         occurrences all number
    26
    23
    4
    3
    Hypoalbuminaemia
         subjects affected / exposed
    10 / 96 (10.42%)
    12 / 98 (12.24%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    18
    19
    0
    0
    Hyponatraemia
         subjects affected / exposed
    8 / 96 (8.33%)
    14 / 98 (14.29%)
    0 / 27 (0.00%)
    0 / 23 (0.00%)
         occurrences all number
    13
    19
    0
    0
    Hypophosphataemia
         subjects affected / exposed
    12 / 96 (12.50%)
    8 / 98 (8.16%)
    1 / 27 (3.70%)
    1 / 23 (4.35%)
         occurrences all number
    17
    10
    1
    1
    Hypomagnesaemia
         subjects affected / exposed
    11 / 96 (11.46%)
    8 / 98 (8.16%)
    0 / 27 (0.00%)
    1 / 23 (4.35%)
         occurrences all number
    17
    15
    0
    1
    Hyperglycaemia
         subjects affected / exposed
    4 / 96 (4.17%)
    5 / 98 (5.10%)
    3 / 27 (11.11%)
    0 / 23 (0.00%)
         occurrences all number
    8
    10
    3
    0
    Hypocalcaemia
         subjects affected / exposed
    7 / 96 (7.29%)
    8 / 98 (8.16%)
    0 / 27 (0.00%)
    2 / 23 (8.70%)
         occurrences all number
    9
    11
    0
    2
    Hypervolaemia
         subjects affected / exposed
    7 / 96 (7.29%)
    4 / 98 (4.08%)
    1 / 27 (3.70%)
    0 / 23 (0.00%)
         occurrences all number
    8
    4
    1
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    16 Feb 2021
    In response to regulatory feedback received from the FDA, the participant population had been expanded to include all TP53 mutant AML participants irrespective of their fitness to receive intensive chemotherapy. This necessitated that an additional control arm (7+3 chemotherapy) be included for participants appropriate for intensive chemotherapy, allowing physician’s choice between venetoclax +azacitidine or 7+3 chemotherapy for the control arm. Various sections of the protocol were modified to reflect this change.
    28 Apr 2021
    A clinical trial application was submitted via the Voluntary Harmonization Procedure (VHP), including the following countries: Belgium, Denmark, France, Germany, Italy, Spain, and Sweden. In response to regulatory feedback received from the Reference National Competent Authority (Ref-NCA), Paul-Ehrlich-Institut (PEI) in Germany, various sections of the protocol were modified to reflect Gilead’s response to the grounds for non-acceptance (GNA).
    09 Aug 2021
    The protocol had been amended primarily to: - Incorporate changes based on feedback from the United States (US) Food and Drug Administration (FDA). - Incorporate changes based on feedback from the Medicines and Healthcare products Regulatory Agency (MHRA). To highlight the cumulative differences between the original protocol and Amendment 3 of the protocol, changes/additions were in bold italicized font and deletions are depicted with strikethrough text.
    31 Mar 2022
    The primary reason for this amendment was to provide additional guidance for enhanced anemia management. Anemia is a known and well-described risk for magrolimab that could occur in early doses and is transient. Adequate monitoring and management of anemia during the first 2 doses of magrolimab are needed to ensure patient safety, especially in participants with low baseline hemoglobin. A minimum hemoglobin threshold prior to the first 2 doses of magrolimab treatment during treatment initiation along with hemoglobin monitoring after magrolimab treatment were included in the protocol. This amendment was also to allow the enrollment of participants based on local TP53 testing results, after central review. This minimized the time participants already diagnosed with TP53-mutated AML had to wait before starting treatment. The study added an interim superiority analysis to be conducted after 128 deaths (75% of the expected 171 overall survival events) were observed in participants appropriate for non-intensive therapy.

    Interruptions (globally)

    Were there any global interruptions to the trial? Yes
    Date
    Interruption
    Restart date
    07 Feb 2024
    The study met futility based on an adhoc analysis with futility assessment conducted in August 2023, and sites were informed of the outcome and sponsor’s decision to terminate the study earlier than planned in a communication in September 2023.
    -

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 19:27:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA